Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 23, 2019

Harpoon begins dosing in Phase I/IIa solid tumours study

Harpoon Therapeutics has commenced dosing of patients in a Phase I/IIa clinical trial being conducted to evaluate HPN536 for the treatment of solid tumours.

Harpoon Therapeutics has commenced dosing of patients in a Phase I/IIa clinical trial being conducted to evaluate HPN536 for the treatment of solid tumours.

Based on the company’s Tri-specific T cell Activating Construct (TriTAC) platform, HPN536 is meant to target mesothelin expressed on cells of ovarian and pancreatic carcinoma, mesothelioma, non-small cell lung cancer, and breast cancer.

The TriTAC platform uses patient’s own immune cells to destroy tumours, and HPN536 is Harpoon’s second TriTAC-based candidate to enter the clinical phase.

During the multi-centre Phase I/IIa trial, HPN536’s safety, tolerability, pharmacokinetics and activity will be assessed in up to 80 patients with mesothelin-expressing cancers.

“The dose escalation portion of the trial will focus on patients with ovarian cancer, where mesothelin is overexpressed.”

The Phase I dose escalation part of the trial is intended to establish a dose for further clinical studies. This portion will enrol around 20 ovarian cancer patients who will receive a once-weekly intravenous infusion of the drug candidate.

Primary outcome measures of the Phase I part are safety, tolerability, and determination of a dose for the Phase II portion.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The dose escalation phase will be followed by a further assessment of the safety and activity of HPN536 in around three other parallel cohorts of 20 patients each with ovarian, pancreatic and mesothelioma cancer.

Harpoon Therapeutics chief medical officer Natalie Sacks said: “The dose escalation portion of the trial will focus on patients with ovarian cancer, where mesothelin is overexpressed in a high percentage of patients.

“HPN536 is a targeted, off-the-shelf immunotherapy that has been optimised for delivery to solid tumours and designed to provide a novel way to engage a patient’s own immune cells to fight cancer for patients who have limited treatment options.”

The Phase I/IIa trial has been initiated at Sarah Cannon Research Institute and is expected to be completed in 2021.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU